Published in J Exp Med on July 01, 1983
Interaction of chlamydiae and host cells in vitro. Microbiol Rev (1991) 8.10
Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J Clin Invest (1983) 5.88
Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect Immun (1986) 4.34
Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun (1994) 2.58
Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun (1989) 2.25
Capacity of recombinant gamma interferon to activate macrophages for Salmonella-killing activity. Infect Immun (1989) 2.20
Inhibition of Chlamydia trachomatis growth by recombinant tumor necrosis factor. Infect Immun (1988) 2.04
Interferon-gamma-induced transcriptional activation is mediated by protein kinase C. Proc Natl Acad Sci U S A (1988) 1.97
In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect Immun (1990) 1.42
Regulation of macrophage function by interferon-gamma. Somatic cell genetic approaches in murine macrophage cell lines to mechanisms of growth inhibition, the oxidative burst, and expression of the chronic granulomatous disease gene. J Clin Invest (1990) 1.37
Fate of Chlamydia trachomatis in human monocytes and monocyte-derived macrophages. Infect Immun (1986) 1.28
Molecular cloning of a gene selectively induced by gamma interferon from human macrophage cell line U937. Mol Cell Biol (1989) 1.23
Lymphokine activation of J774G8 cells and mouse peritoneal macrophages challenged with Toxoplasma gondii. Infect Immun (1985) 1.11
Oxygen-independent killing by alveolar macrophages. J Exp Med (1986) 1.11
Acquired immunity in experimental murine aspergillosis is mediated by macrophages. Infect Immun (1993) 1.07
Involvement of reactive oxygen intermediates in tumor necrosis factor alpha-dependent bacteriostasis of Mycobacterium avium. Infect Immun (1996) 1.06
Cellular defenses against Toxoplasma gondii in newborns. J Clin Invest (1984) 1.05
Inhibition of human neutrophil NADPH oxidase by Chlamydia serovars E, K, and L2. Infect Immun (1989) 1.02
Inhibition of Chlamydia trachomatis replication in HEp-2 cells by human monocyte-derived macrophages. Infect Immun (1988) 0.99
Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins. Front Immunol (2014) 0.92
Activation of monocytes by interferon-gamma has no effect on the level or affinity of the nicotinamide adenine dinucleotide-phosphate oxidase and on agonist-dependent superoxide formation. J Clin Invest (1988) 0.81
Oxidative metabolic response and microbicidal activity of human milk macrophages: effect of lipopolysaccharide and muramyl dipeptide. Infect Immun (1985) 0.76
Opportunistic infections and impaired cell-mediated immune responses in patients with the acquired immune deficiency syndrome. Trans Am Clin Climatol Assoc (1984) 0.75
Toxoplasma Effectors Targeting Host Signaling and Transcription. Clin Microbiol Rev (2017) 0.75
Immunologic and clinicopathologic evaluation of adult dogs inoculated with Encephalitozoon cuniculi. J Clin Microbiol (1988) 0.75
Failure to trigger the oxidative metabolic burst by normal macrophages: possible mechanism for survival of intracellular pathogens. J Exp Med (1980) 5.23
Activation of macrophages in vivo and in vitro. Correlation between hydrogen peroxide release and killing of Trypanosoma cruzi. J Exp Med (1979) 5.22
Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med (1979) 3.72
Assessment in vitro of immunity against Toxoplasma gondii. J Exp Med (1975) 3.50
Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation. J Exp Med (1980) 3.43
Temporal changes of lysosome and phagosome pH during phagolysosome formation in macrophages: studies by fluorescence spectroscopy. J Cell Biol (1981) 3.27
Macrophage microbicidal activity. Correlation between phagocytosis-associated oxidative metabolism and the killing of Candida by macrophages. J Exp Med (1980) 2.96
Lymphokine-mediated microbistatic mechanisms restrict Chlamydia psittaci growth in macrophages. J Immunol (1982) 2.40
Lymphokines enhance the capacity of human monocytes to secret reactive oxygen intermediates. J Clin Invest (1982) 2.23
Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J Exp Med (1981) 2.22
Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J Immunol (1982) 2.09
Role for endogenous and acquired peroxidase in the toxoplasmacidal activity of murine and human mononuclear phagocytes. J Clin Invest (1982) 1.64
Suppression of macrophage oxidative metabolism by products of malignant and nonmalignant cells. J Exp Med (1982) 1.58
Inhibition of Chlamydia psittaci in oxidatively active thioglycolate-elicited macrophages: distinction between lymphokine-mediated oxygen-dependent and oxygen-independent macrophage activation. Infect Immun (1983) 1.53
A role for oxygen-dependent mechanisms in killing of Leishmania donovani tissue forms by activated macrophages. J Immunol (1982) 1.36
Pretreatment with phorbol myristate acetate inhibits macrophage activity against intracellular protozoa. J Reticuloendothel Soc (1982) 1.32
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 14.08
An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med (1981) 7.35
Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J Clin Invest (1983) 5.88
Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev (1994) 4.94
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med (1984) 4.73
Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect Immun (1986) 4.34
The macrophage as an effector cell. N Engl J Med (1980) 4.30
Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro. Proc Natl Acad Sci U S A (1993) 4.28
Parasite-specified phagocytosis of Chlamydia psittaci and Chlamydia trachomatis by L and HeLa cells. Infect Immun (1978) 4.26
Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol (1985) 3.85
Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med (1984) 3.73
Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med (1979) 3.72
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis (2000) 3.72
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Gamma-interferon is the factor in lymphokine that activates human macrophages to inhibit intracellular Chlamydia psittaci replication. J Immunol (1983) 3.49
Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation. J Exp Med (1980) 3.43
Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun (1997) 3.12
Requirements for ingestion of Chlamydia psittaci by mouse fibroblasts (L cells). Infect Immun (1976) 3.11
Killing of intracellular Leishmania donovani by human mononuclear phagocytes. Evidence for oxygen-dependent and -independent leishmanicidal activity. J Clin Invest (1983) 3.06
The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med (1975) 3.06
Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med (1984) 3.02
Macrophage oxygen-dependent antimicrobial activity. I. Susceptibility of Toxoplasma gondii to oxygen intermediates. J Exp Med (1979) 2.93
Lymphokine-mediated inhibition of Chlamydia replication in mouse fibroblasts is neutralized by anti-gamma interferon immunoglobulin. Infect Immun (1983) 2.77
Immediate toxicity of high multiplicities of Chlamydia psittaci for mouse fibroblasts (L cells). Infect Immun (1976) 2.76
Serious infections from Bacillus sp. JAMA (1979) 2.67
Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun (1994) 2.58
A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun (1990) 2.55
Streptococcus bovis bacteremia and underlying gastrointestinal disease. Arch Intern Med (1978) 2.54
Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease. Trends Microbiol (1994) 2.54
Serious infections caused by Streptococcus milleri. Am J Med (1978) 2.47
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol (1987) 2.45
Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. J Immunol (1982) 2.42
Lymphokine-mediated microbistatic mechanisms restrict Chlamydia psittaci growth in macrophages. J Immunol (1982) 2.40
Liver macrophages in murine listeriosis. Cell-mediated immunity is correlated with an influx of macrophages capable of generating reactive oxygen intermediates. J Exp Med (1985) 2.37
Role in vivo for gamma interferon in control of pneumonia caused by Chlamydia trachomatis in mice. Infect Immun (1988) 2.30
Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun (1989) 2.25
Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J Exp Med (1981) 2.22
Effect of interferon on the growth of Chlamydia trachomatis in mouse fibroblasts (L cells). Infect Immun (1983) 2.17
Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J Immunol (1982) 2.09
Murine Kupffer cells. Mononuclear phagocytes deficient in the generation of reactive oxygen intermediates. J Exp Med (1985) 2.03
Human mononuclear phagocyte antiprotozoal mechanisms: oxygen-dependent vs oxygen-independent activity against intracellular Toxoplasma gondii. J Immunol (1985) 2.00
Kinetics of phagocytosis of Chlamydia psittaci by mouse fibroblasts (L cells): separation of the attachment and ingestion stages. Infect Immun (1978) 1.94
Circulating Borrelia burgdorferi in patients with acute Lyme disease: results of blood cultures and serum DNA analysis. J Infect Dis (1993) 1.88
Atypical pneumonias. Med Clin North Am (1980) 1.88
Oxygen-independent inhibition of intracellular Chlamydia psittaci growth by human monocytes and interferon-gamma-activated macrophages. J Immunol (1986) 1.87
Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J Immunol (1988) 1.87
Patients at risk for AIDS-related opportunistic infections. Clinical manifestations and impaired gamma interferon production. N Engl J Med (1985) 1.87
Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med (1997) 1.80
Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis (1999) 1.79
Malaria--the mime revisited: fifteen more years of experience at a New York City teaching hospital. Am J Med (1992) 1.77
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74
Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. Am J Hosp Pharm (1979) 1.72
Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med (1981) 1.71
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70
Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol (1989) 1.70
Salmonella infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1985) 1.69
Regulation of arachidonic acid metabolism by macrophage activation. J Exp Med (1982) 1.69
Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun (1994) 1.67
Patients treated for amebic liver abscess develop cell-mediated immune responses effective in vitro against Entamoeba histolytica. J Immunol (1986) 1.65
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med (1997) 1.59
Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 1.58
Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis. Ann Trop Med Parasitol (2002) 1.54
Reactivation of persistent Chlamydia trachomatis infection in cell culture. Infect Immun (1995) 1.54
Tumor necrosis factor alpha is a cytotoxin induced by murine Chlamydia trachomatis infection. Infect Immun (1989) 1.54
IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J Immunol (1993) 1.53
Inhibition of Chlamydia psittaci in oxidatively active thioglycolate-elicited macrophages: distinction between lymphokine-mediated oxygen-dependent and oxygen-independent macrophage activation. Infect Immun (1983) 1.53
Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect (1999) 1.52
The dynamics of granuloma formation in experimental visceral leishmaniasis. J Exp Med (1988) 1.51
In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. Studies with normal and AIDS monocytes. J Immunol (1987) 1.51
Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ (2001) 1.50
Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma. J Immunol (1985) 1.50
Antistreptolysin O and anti-deoxyribonuclease B titers: normal values for children ages 2 to 12 in the United States. Pediatrics (1998) 1.50
Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis (1998) 1.49
Cytochalasin B does not inhibit ingestion of Chlamydia psittaci by mouse fibroblasts (L cells) and mouse peritoneal macrophages. Infect Immun (1979) 1.48
T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring. Clin Exp Immunol (1996) 1.48
Septic pulmonary embolism complicating a central venous catheter. Chest (1990) 1.47
Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis (1998) 1.46
Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med (1988) 1.45
Macrophage oxygen-dependent antimicrobial activity. IV. Role of endogenous scavengers of oxygen intermediates. J Exp Med (1980) 1.44
Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol (1994) 1.43
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg (1997) 1.43
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
Immunoelectron-microscopic quantitation of differential levels of chlamydial proteins in a cell culture model of persistent Chlamydia trachomatis infection. Infect Immun (1994) 1.41
Interaction of Leishmania with a macrophage cell line. Correlation between intracellular killing and the generation of oxygen intermediates. J Exp Med (1981) 1.34
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33
Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis (2002) 1.33
Pretreatment with phorbol myristate acetate inhibits macrophage activity against intracellular protozoa. J Reticuloendothel Soc (1982) 1.32
Coping with AIDS. The special problems of New York City. N Engl J Med (1987) 1.31
Antimicrobial therapy in pulmonary aspiration. Am J Med (1979) 1.31
Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis (2000) 1.29
Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome. Infect Immun (2001) 1.28
Arrays of hemispheric surface projections on Chlamydia psittaci and Chlamydia trachomatis observed by scanning electron microscopy. J Bacteriol (1979) 1.26
Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection. Infect Immun (1999) 1.25